Equities Analysts Offer Predictions for VRTX FY2025 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for Vertex Pharmaceuticals in a report issued on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now anticipates that the pharmaceutical company will post earnings of $15.55 per share for the year, down from their previous estimate of $15.60. Cantor Fitzgerald has a “Overweight” rating and a $535.00 price objective on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share.

Other equities research analysts also recently issued reports about the stock. Scotiabank decreased their target price on shares of Vertex Pharmaceuticals from $450.00 to $442.00 and set a “sector perform” rating for the company in a research report on Tuesday, May 6th. Leerink Partners restated a “market perform” rating and set a $503.00 price target (down from $550.00) on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. HC Wainwright restated a “buy” rating and set a $550.00 price target on shares of Vertex Pharmaceuticals in a report on Monday, June 23rd. Erste Group Bank cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, May 23rd. Finally, Bank of America boosted their price target on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the stock a “buy” rating in a report on Monday, March 31st. Fourteen equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $511.62.

Vertex Pharmaceuticals Trading Up 0.1%

NASDAQ:VRTX opened at $479.53 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29. The firm has a 50-day moving average of $448.35 and a 200-day moving average of $459.98. The company has a market cap of $123.14 billion, a PE ratio of -122.33 and a beta of 0.41. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the firm posted $4.76 earnings per share.

Institutional Trading of Vertex Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Activest Wealth Management bought a new stake in Vertex Pharmaceuticals during the 1st quarter worth approximately $25,000. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 45 shares during the last quarter. Mascagni Wealth Management Inc. bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth $31,000. Flaharty Asset Management LLC bought a new position in shares of Vertex Pharmaceuticals in the 1st quarter worth $32,000. Finally, Truvestments Capital LLC increased its holdings in shares of Vertex Pharmaceuticals by 30.3% in the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock worth $40,000 after buying an additional 23 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.